MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press7810.17650/2782-3202-2023-3-3-57-63DIAGNOSTIC CAPABILITIESВОЗМОЖНОСТИ ДИАГНОСТИКИNoninvasive colorectal cancer screening techniques: literature reviewНеинвазивные методы скрининга колоректального рака: обзор литературыhttps://orcid.org/0000-0002-6850-6919VereshchakV. V.ВерещакВ. В.
Russian Federation

Valeria Vadimovna Vereshchak

143081

111 1st Uspenskoe Shosse

Moscow region

Lapino

Валерия Вадимовна Верещак

143081

1-е Успенское шоссе, 111

Московская обл.

Лапино

vvvereshchak@yandex.ruhttps://orcid.org/0000-0002-1345-041XIurichevI. N.ЮричевИ. Н.
Russian Federation

143081

111 1st Uspenskoe Shosse

Moscow region

Lapino

143081

1-е Успенское шоссе, 111

Московская обл.

Лапино

https://orcid.org/0000-0002-5565-615XRasulovA. O.РасуловА. О.
Russian Federation

143081

111 1st Uspenskoe Shosse

Moscow region

Lapino

143081

1-е Успенское шоссе, 111

Московская обл.

Лапино

https://orcid.org/0000-0001-9992-3822MadyarovJ. M.МадьяровЖ. М.
Russian Federation

143081

111 1st Uspenskoe Shosse

Moscow region

Lapino

143081

1-е Успенское шоссе, 111

Московская обл.

Лапино

Clinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»200920233357632009202320092023Copyright ©; 2023, ABV-PressCopyright ©; 2023, АБВ-пресс2023ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/78

   Fecal DNA testing is a noninvasive method recommended by professional medical societies for colorectal cancer screening in individuals with intermediate risk of the disease. Adenamatous and serrated lesions, as well as cancer, lead to exfoliation of cells containing neoplastic altered DNA which, in turn, can be detected with sensitive testing methods aimed at specific genetic and epigenetic biomarkers. Mt-sDNA test approved by the United States Food and Drug Administration in 2014 showed sensitivity of 92 % for detection of colorectal cancer which is much higher than sensitivity of fecal immunochemical test (74 %).

   Исследование ДНК кала – неинвазивный метод, рекомендованный медицинскими профессиональными обществами для скрининга колоректального рака у лиц со средним риском развития заболевания. Аденоматозные и зубчатые образования, а также злокачественные новообразования приводят к отслаиванию клеток, содержащих неопластические измененные ДНК, которые, в свою очередь, могут быть обнаружены с помощью чувствительных методов анализа, нацеленных на конкретные генетические и эпигенетические биомаркеры. Тест ДНК (mt-sDNA), который был одобрен Управлением по контролю за качеством пищевых продуктов и лекарственных средств США в 2014 г., показал чувствительность 92 % для выявления колоректального рака, что намного выше чувствительности иммунохимического тестирования кала (74 %).

colorectal cancer screeningfecal testDNAскрининг колоректального ракаисследование калаДНКThe work was performed without external fundingРабота выполнена без спонсорской поддержкиNishihara R., Wu K., Lochhead P. et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369(12):1095–105. DOI: 10.1056/NEJMoa1301969Zauber A., Winawer S.J., O’Brien M.J. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366(8):687–96. DOI: 10.1056/NEJMoa1100370Shaukat A., Mongin S.J., Geisser M.S. et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369(12):1106–14. DOI: 10.1056/NEJMoa1300720Rex D.K., Boland C.R., Dominitz J.A. et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017;153(1):307–23. DOI: 10.1053/j.gastro.2017.05.013Carethers J.M. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci 2015;60(3):711–21. DOI: 10.1007/s10620-014-3443-5Ahlquist D.A. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci 2015;60(3):623–33. DOI: 10.1007/s10620-014-3451-5Lin J.S., Webber E.M., Beil T.L. et al. Fecal DNA testing in screening for colorectal cancer in average-risk adults: comparative effectiveness review. Rockville, MD: Agency for Healthcare Research and Quality, 2012. Available at: https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-screening_executive.pdfCarethers J.M. DNA testing and molecular screening for colon cancer. Clin Gastroenterol Hepatol 2014;12(3):377–81. DOI: 10.1016/j.cgh.2013.12.007.Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135(4):1079–99. DOI: 10.1053/j.gastro.2008.07.076Carethers J.M., Jung B.H. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 2015;149(5):1177–90. DOI: 10.1053/j.gastro.2015.06.047Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–7. DOI: 10.1038/nature11252Carethers J.M. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans Am Clin Climatol Assoc 2016;127:81–97.Carethers J.M. Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep 2017;13(1):73–80. DOI: 10.1007/s11888-017-0352-yCarethers J.M., Fearon E.R. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 2015;148(1):10–3. DOI: 10.1053/j.gastro.2014.11.024Koi M., Garcia M., Choi C. et al. Microsatellite alterations with allelic loss on 9p24.2 signify less aggressive colorectal cancer metastasis. Gastroenterology 2016;150(4):944–55. DOI: 10.1053/j.gastro.2015.12.032Coppede F., Lopomo A., Spisni R., Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 2014;20(4):943–56. DOI: 10.3748/wjg.v20.i4.943Carethers J.M. Biomarker-directed targeted therapy in colorectal cancer. J Dig Cancer Rep 2015;3(1):5–10.Klaassen C.H., Jeunink M.A., Prinsen C.R. et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;49(7):1185–87. DOI: 10.1373/49.7.1185Anderson B.W., Ahlquist D.A. Molecular detection of gastrointestinal neoplasia. Innovations in early detection and screening. Gastroenterol Clin N Am 2016;45(3):529–42. DOI: 10.1016/j.gtc.2016.04.009Sidransky D., Tokino T., Hamilton S.R. et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256(5053):102–5. DOI: 10.1126/science.1566048Shen L., Toyota M., Kondo Y. et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007;104(47):18654–59. DOI: 10.1073/pnas.0704652104Imperiale T.F., Ransohoff D.F., Itzkowitz S.H. et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med 2004;351(26):2704–14. DOI: 10.1056/NEJMoa033403Bailey J.R., Aggarwal A., Imperiale T.F. Colorectal cancer screening: stool DNA and other noninvasive modalities. Gut Liver 2016;10(2):204–11. DOI: 10.5009/gnl15420Cologuard® physician brochure. Exact Sciences Corp. Madison, WI: Exact Sciences Corp. Available at: https://cdn2.hubspot.net/hub/377740/file-1412311339-pdf/Document__LBL-0260[1].pdf?t=1534449532931Imperiale T.F., Ransohoff D.F., Itzkowitz S.H. et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287–97. DOI: 10.1056/NEJMoa1311194Ahlquist D.A., Zou H., Domanico M. et al. Next generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142(2):248–56. DOI: 10.1053/j.gastro.2011.10.031Redwood D.G., Asay E.D., Blake I.D. et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin Proc 2016;91(1):61–70. DOI: 10.1016/j.mayocp.2015.10.008Yang D., Hillman S.L., Harris A.M. et al. Patient perceptions of a stool DNA testing for pandigestive cancer screening: a survey questionnaire. World J Gastroenterol 2014;20(17):4972–79. DOI: 10.3748/wjg.v20.i17.4972Cooper G.S., Markowitz S.D., Chen Z. et al. Evaluation of patients with an apparent false positive stool DNA test: the role of repeat stool testing. Dig Dis Sci 2018;63(6):1449–53. DOI: 10.1007/s10620-018-5001-zJohnson D.H., Kisiel J.B., Burger K.N. et al. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Gastrointest Endosc 2017;85(3): 657–65.e.1. DOI: 10.1016/j.gie.2016.11.012